key: cord-0862939-cx6ahyvh authors: Oladele, Johnson Olaleye; Oyeleke, Oyedotun Moses; Oladele, Oluwaseun Titilope; Oladiji, Adenike Temidayo title: Covid-19 treatment: Investigation on the phytochemical constituents of Vernonia amygdalina as potential Coronavirus-2 inhibitors date: 2021-02-18 journal: Comput Toxicol DOI: 10.1016/j.comtox.2021.100161 sha: 254be82d76ce45d7dfe057f27078cba9563c7c50 doc_id: 862939 cord_uid: cx6ahyvh The upsurge in the current cases of COVID-19 poses a major threat on human health and population all over the globe. The emergence of new infectious diseases and increase in frequency of drug resistant viruses demand effective and novel therapeutic agents. In this study, we used bioinformatics approach to investigate the possible inhibitory potentials of phytochemical constituents of Vernonia amygdalina towards coronavirus-2 major protease. Pharmacodynamics, pharmacokinetics and toxicological profiles of the compounds were also examined using the pkCSM server. All the phytochemicals showed good binding affinity to the binding pocket of PDB ID 6LU7. It was observed that veronicoside A exhibited the highest binding affinity when compared to remdesivir, hydroxy-vernolide, vernodalin, vernodalol, and vernolide. The amino acids LEU272, LEU287, GLY275, TYR237, LYS236, THR198, THR199, ARG131, and LYS5 were showed as the key residues for veronicoside A binding to human SARS-COV2 major protease. The Pharmacodynamics and pharmacokinetics results suggested that all the tested phytochemicals have significant drug likeness properties and they could be absorbed through the human intestine. Furthermore, all the tested phytochemicals are not hepatoxic and also exhibited non or relatively low toxic effects in human. Taken together, the results of this study indicated that all the tested phytochemicals are potential putative inhibitors of SARS-COV2 major protease with non or low toxicity effects. However, further experimental and clinical studies are needed to further explore their activities and validate their efficacies against COVID-19. Novel Coronavirus disease 2019 (COVID- 19) , ranked among the ninth deadliest world pandemic, is a highly infectious and severe acute respiratory disorder caused by a morbific virus called SARS-CoV-2 which is transmitted to humans via contact with infected persons and/or feeding on infected animals. The COVID-19 clinical manifestations are very similar to viral pneumonia such as fever, fatigue, cough, shortness of breath, and other complications. According to reports obtained on WHO and NCDC websites as of 27 th June 2020, the coronavirus breakout in Wuhan, a city in Hubei Province of China in November 2019 and has spread to many countries in the world. This global pandemic has forced many nations to lock down their social and economic activities which in turn have adverse effects on the economy. Globally, more than ten million people have been confirmed infected with over 500,000 deaths. Nigeria is one of the countries seriously affected by the virus having over 25,000 cases and more than 500 mortalities [1, 2] . Thus, there is an exigent need for effective and non-invasive treatment. Coronaviruses (SARS-CoV) are non-segmented positive-sense single-stranded RNA viruses with a large viral RNA genome of diameter 80-120 nm [26] . They belong to the family of Coronaviridae, in the subfamily Orthocoronaviridae which consists of four genera namely: Alpha, Beta, Gamma, and Delta coronavirus [3] . Some of the modes of actions of SARS-CoV-2 include hyper-inflammation characterized by a sudden and fatal hyper-cytokinaemia with multi-organ failure [4] ; immunosuppression; reduction of Angiotensin-Converting Enzyme 2 (ACE2) to enhance pulmonary vascular permeability and damage the alveoli [5] ; and activated by ORF3a, ORF3b, and ORF7a via JNK pathway which induces lung damage [6] . At present, there is no known effective treatment that can mitigate/inhibit the pathogenesis of coronavirus in infected patients, however, there is vaccine to prevent the wide spread of the virus. Available clinical interventions for COVID-19 patients are only palliative and limited to support. There is still urgent need for therapeutic agents as cases of infections is increasing on the daily basis. Therefore, many research groups around the world are currently focusing on developing novel antivirals using various in silico methods [28] [29] [30] . This research investigated the inhibitory potentials of some naturally occurring phytochemicals present in Vernonia amygdalina against COVID-19 major protease (6LU7). Vernonia amygdalina, commonly known as bitter leaf, is an indigenous African plant with a number of scientific proven medicinal importance [10, [31] [32] [33] . These phytochemicals can be repurposed to mitigate the pathogenesis of the SARS-CoV-2 and thus put an end to the frightening associated mortality rate. The crystal structure of SARS-COV2 major protease (PDB ID 6LU7) with resolution 2.16 Å was retrieved from the protein databank (www.rcsb.org). Prior to docking and analysis, the crystal structure was prepared by removing existing ligands and water molecules. Also, missing hydrogen atoms were added using Autodock v4.2 program, Scripps Research Institute [27] . Thereafter, nonpolar hydrogens were merged while polar hydrogen was added and subsequently saved into pdbqt format in preparation for molecular docking. The SDF structures of selected phytochemical constituents of the leaf extract of Vernonia amygdalina: hydroxyvernolide, vernodalin, vernodalol, vernolide, and veronicoside were retrieved from the PubChem database (www.pubchem.ncbi.nlm.nih.gov). The phytochemicals were converted to mol2 chemical format. Polar hydrogens were added while non-polar hydrogens were merged with the carbons and the internal degrees of freedom and torsions were set. The protein and ligand molecules were further converted to the dockable PDBQT format using Autodock tools. Docking of the phytochemicals to the targeted protein and determination of binding affinities was carried out using AutodockVina [7] . The PDBQT formats of the receptor and that of the The conformational stability of the protein-ligand interactions was evaluated using molecular dynamics simulations analysis performed through iMODS server (http://imods.chaconlab.org) by normal mode analysis (NMA) predicting properties such as deformability, mobility profiles, eigenvalues, variance, co-variance map and elastic network of the protein-ligand interactions [8] . The solubility, pharmacodynamics, pharmacokinetics and toxicological profiles of hydroxyvernolide, vernodalin, vernodalol, vernolide, veronicoside and remdesivir were computed based on their ADMET (absorption, distribution, metabolism, elimination, and toxicity) studies using pkCSM tool (http://biosig.unimelb.edu.au/pkcsm/prediction) as described by Pires et al., (2015) . The canonical SMILE molecular structures of the compounds used in the studies were obtained from PubChem (https://pubchem.ncbi.nlm.nih.gov). The molecular docking analysis and visualization of 6LU7 binding with remdesivir, hydroxyvernolide, vernodalin, vernodalol, vernolide, and veronicoside A is shown in figure 1, figure 2 and Table 1 . Out of the all the tested compounds, veronicoside A exhibited the best docked score (-7. The predicted absorption properties of each of the phytochemicals were reported in table 3. The result showed that veronicoside A has the highest water solubility value of -2.886 while vernolide has the lowest valve of -3.936. Vernolide has the highest permeability value of 0.804, but veronicoside A having the least permeability valve of -1.469. Likewise, vernolide can be readily absorbed by the intestinal cells (100%) whereas veronicoside A may not be absorbed intestine. All the phytochemicals are substrate of P-glycoprotein and none of the phytochemicals is neither inhibitor of P-glycoprotein-I nor P-glycoprotein-II. Table 4 showed the predicted in vivo distribution of the phytochemicals. All the phytochemicals tested have relatively low steady-state volume of distribution. Also, the predicted result revealed that hydroxy-vernolide has the highest unbound fraction in the human blood. All the phytochemicals have relatively low blood-brain barrier and CNS permeability values. The predicted clearance of each of the phytochemicals were reported in table 6. Hydroxy-vernolide has the highest total clearance rate of 1.267 while Veronicoside A has the least clearance rate of -0.356. None of the phytochemicals is substrate of renal organic cation transporter. Table 7 reported the predicted toxicological profile of all the tested phytochemicals. Hydroxyvernolide, vernolide, and veronicoside A has no mutagenic potentials against bacteria (AMES toxicity) but vernodalol and vernodalin could be toxic to bacteria. None of the phytochemicals has adverse effects on the hepatic or dermal cells. The phytochemicals are not inhibitors of human ether-a-go-go-related gene (hERG) hERG I and hERG II except veronicoside A which may inhibit hERG II. All the phytochemicals have relatively low maximum recommended tolerated dose values. Plants belonging to the Vernonia genus is principally known to house huge amounts of sesquiterpene lactones with several documented pharmacological and biological activities [9] . Vernonia amygdalina is a member of this group of plants and normally called bitter leaf. It is a medicinal plant used traditionally in the management and treatment of different diseases such as respiratory diseases, cough, reproductive diseases [10] . This present study examines the possible inhibitory activity of selected phytochemical constituents (hydroxyvernolide, vernodalin, vernodalol, vernolide, and veronicoside) of the leaf extract of Vernonia amygdalina against SARS-COV2 major protease (6LU7). As shown in the result, veronicoside A exhibited the highest affinity with 6LU7. This indicates that veronicoside can be a putative inhibitor of coronavirus-2. Veronicoside has been reported to have radical scavenging and antioxidant activities. It has also been documented to have cytotoxicity activities against Hep-2 (human larynx epidermoid carcinoma), RD (human rhabdomyosarcoma), and L-20B (transgenic murine cells) cell lines [11] . Several species of plants containing veronicoside are being used in traditional medicine to treat influenza, respiratory diseases, hernia, cough, laryngopharyngitis, cancer, hemoptysis, and are also used as an antiscorbutic and expectorant [12] . Vernodalin and vernolide also showed a good binding affinity with the coronavirus-2 major protease, suggesting them as potential suitable inhibitors of the virus. Vernodalin and vernolide have been reported to exhibit antiproliferative activities [13] against lung A549 (adenocarcinomic human alveolar basal epithelial cells), HeLa, and MDA-MB-23 (human breast cancer) cell lines and induced apoptosis on HepG2 cells with G2/M phase cell cycle arrest [14] . They have potential to be used as lead compounds in the development of a therapeutic natural product for treatment of cancers in the lungs, breast or liver. These phytochemicals may also offer help in inhibiting the proliferative activities of SARS-COV2 in the host thereby mitigate the pathogenesis of COVID- Sinisi et al [15] has reported vernodalol has a good activator of Nrf2. NF-E2-related factor-2 (NRF2) is a transcriptional factor that binds to and facilitates the activation of the ARE-dependent gene. Under basal conditions, NRF2 is sequestered in the cytoplasm and its expression is maintained to be low due to constant polyubiquitination. In response to different kinds of stress, Nuclear Factor kappa-light-chain-enhancer of activated B-cells (NF-kB) pathway has been implicated in the mode of actions of SARS-COV2 [16, 17] leading to a cytokine profile resembling secondary haemophagocytic lymphohistiocytosis (sHLH) with a hyperinflammatory syndrome characterized by a fulminant and severe hypercytokinaemia with multiorgan failure. This is characterized by increased tumor necrosis factor-α, interleukin (IL)-2, IL-7, interferon-γ inducible protein 10, granulocyte-colony stimulating factor, macrophage inflammatory protein 1-α, and monocyte chemoattractant protein 1 [18] . However, vernolide and vernodalol have been documented to show marked inhibitory activity on STAT3/NF-κB [15] . Therefore, vernolide and vernodalol could protect against COVID-19-induced multiorgan failure by suppressing the hyperinflammatory syndrome via inhibition of NF-kB. The results of the solubility, pharmacodynamics, pharmacokinetics and toxicological profiles of remdesivir, hydroxy-vernolide, vernodalin, vernodalol, vernolide, and veronicoside A are presented in Tables 2-7 . The profiles were investigated as a systemic virtual screening of drugs and potential drugs. This is done as alternative to in vivo examinations which are essential complements in drug discovery. The Lipinski's rule is a major criterion to evaluate drug likeliness and to determine if a compound with a particular pharmacological and biological actions has physical and chemical properties that could favour its activities in human. The molecular properties of the compounds based on the computed partition coefficient (log P) showed that the phytochemicals have relatively good lipophilicity as the logP values were less than 5 [19, 20] . All the tested phytochemicals could be maintained in the system at appropriate concentrations. Intestinal absorption and Caco2 permeability are parameters that determine the ultimate bioavailability of drug candidates. The tested phytochemicals (hydroxy-vernolide, vernodalin, vernodalol, vernolide, and veronicoside A) have relatively low Caco2 permeability potential (<8×10 -6 cm/s) and could be absorbed through the human intestine [21] . However, ADMETSAR1 as predicted that remdesivir is subcellular localization in the lysosome [22] . Furthermore, the observed lipophilicities have an association with Caco2 permeability but correlated negatively with water solubility potentials of the tested phytochemicals. This result is in tandem with the findings of Yazdanian et al [23] who used the human colon adenocarcinoma (Caco-2) cell line assay to document no correlation between the drug permeability and measured lipophilicity. All the tested phytochemicals were predicted to be substrates of P-glycoprotein, a member of the ATPbinding cassette transporter and an efflux membrane transporter found chiefly in epithelial cells. On the other hand, none of the phytochemicals is predicted as P-glycoprotein inhibitors except remdesivir. This indicate that they don't alter the normal physiological activities of P-glycoprotein including restricting the active uptake and the distribution of drugs [24] . The volume of distribution calculated using a steady-state volume of distribution (VDss) as predicted showed that vernodalin has the lowest theoretical dose required for uniform distribution in the plasma when compared with other tested phytochemicals (hydroxy-vernolide, vernodalol, vernolide, and veronicoside A). VDss showed the distribution of drug in the tissue and plasma. The degree of diffusing across plasma membrane increases in this order hydroxyvernolide< vernodalol < vernolide